Contact
searchSearch
HMP Global

Alzheimer Disease News

News
Fine Particulate Air Pollution Linked to Greater Alzheimer Neuropathology, Study Finds
12/16/2025
Grace Taylor, MS, MA
Research published in JAMA Neurology links higher exposure to fine particulate air pollution (PM2.5) with more severe Alzheimer-related brain changes and faster cognitive decline in older adults.
Research published in JAMA Neurology links higher exposure to fine particulate air pollution (PM2.5) with more severe Alzheimer-related brain changes and faster cognitive decline in older adults.
Research published in JAMA...
12/16/2025
Annals of Long-Term Care
News
Gabapentin Enacarbil Lowers Nighttime Agitation in Dementia Patients With Restless Legs Syndrome
11/26/2025
Grace Taylor, MS, MA
A randomized trial shows that treating restless legs syndrome with gabapentin enacarbil can significantly reduce nighttime agitation and improve sleep in older adults with Alzheimer disease–related dementia.
A randomized trial shows that treating restless legs syndrome with gabapentin enacarbil can significantly reduce nighttime agitation and improve sleep in older adults with Alzheimer disease–related dementia.
A randomized trial shows that...
11/26/2025
Annals of Long-Term Care
A man lies in bed asleep
News
Moderate to Severe OSA May Raise Risk for Cerebral Microbleeds
11/03/2025
Jolynn Tumolo
Moderate to severe obstructive sleep apnea (OSA) is independently linked with an increased risk of incident cerebral microbleeds (CMBs) over 8 years, according to a population-based study published online in JAMA Network Open.
Moderate to severe obstructive sleep apnea (OSA) is independently linked with an increased risk of incident cerebral microbleeds (CMBs) over 8 years, according to a population-based study published online in JAMA Network Open.
Moderate to severe obstructive...
11/03/2025
Neurology
a neurologist reviews a brain model with a patient
News
Posttreatment Amyloid Levels Associated With Donanemab Benefit in Early AD
10/28/2025
Jolynn Tumolo
An exploratory post hoc analysis of a randomized clinical trial that demonstrated clinical benefit with donanemab in patients with early symptomatic Alzheimer disease (AD) suggests amyloid plaque removal was the mechanism of action.
An exploratory post hoc analysis of a randomized clinical trial that demonstrated clinical benefit with donanemab in patients with early symptomatic Alzheimer disease (AD) suggests amyloid plaque removal was the mechanism of action.
An exploratory post hoc analysis...
10/28/2025
Neurology
A doctor clasps an elderly woman's hand between her own alzheimer's cognitive impairment
News
Metabolic Modulators Show Promise in Early Alzheimer Disease
10/21/2025
Jolynn Tumolo
Intranasal insulin and the diabetes drug empagliflozin were safe and demonstrated positive effects on memory, brain health, and brain blood flow in patients with mild cognitive impairment (MCI) and early Alzheimer disease (AD).
Intranasal insulin and the diabetes drug empagliflozin were safe and demonstrated positive effects on memory, brain health, and brain blood flow in patients with mild cognitive impairment (MCI) and early Alzheimer disease (AD).
Intranasal insulin and the...
10/21/2025
Neurology
US FDA sign
News
FDA Clears New Blood Test for Alzheimer Disease in Primary Care Settings
10/17/2025
Brionna Mendoza
On Monday, the US Food and Drug Administration (FDA) cleared the Elecsys pTau181 blood-based biomarker test to aid in the initial assessment for Alzheimer disease (AD) and other causes of cognitive decline, for use in primary care settings....
On Monday, the US Food and Drug Administration (FDA) cleared the Elecsys pTau181 blood-based biomarker test to aid in the initial assessment for Alzheimer disease (AD) and other causes of cognitive decline, for use in primary care settings....
On Monday, the US Food and Drug...
10/17/2025
Neurology
an illustration of a head in profile with brain against a pink background
News
Noninvasive Physiomarker Identifies MCI and AD With High Accuracy
09/16/2025
Jolynn Tumolo
A novel physiological marker that quantifies the regulation dynamics of cerebral perfusion and oxygenation surpassed the performance of cognitive assessment tests and amyloid positron emission tomography (PET) in differentiating patients with...
A novel physiological marker that quantifies the regulation dynamics of cerebral perfusion and oxygenation surpassed the performance of cognitive assessment tests and amyloid positron emission tomography (PET) in differentiating patients with...
A novel physiological marker...
09/16/2025
Neurology
FDA approval stamp
News
FDA Approves Subcutaneous Injection for Maintenance Treatment of Early AD
09/11/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once-weekly subcutaneous lecanemab-irmb injections (LEQEMBI IQLIK) for the maintenance treatment of early Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once-weekly subcutaneous lecanemab-irmb injections (LEQEMBI IQLIK) for the maintenance treatment of early Alzheimer disease (AD).
The US Food and Drug...
09/11/2025
Neurology
Mediterranean diet
News
Mediterranean Diet May Mitigate Genetic Risk for Alzheimer Disease
09/05/2025
Brionna Mendoza
For those carrying the APOE4 gene, following a Mediterranean diet may lower the risk of developing Alzheimer disease and dementia, suggest study results published in Nature Medicine.
For those carrying the APOE4 gene, following a Mediterranean diet may lower the risk of developing Alzheimer disease and dementia, suggest study results published in Nature Medicine.
For those carrying the APOE4...
09/05/2025
Neurology
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Alzheimer Disease Drugs Show Double the Impact in Long-Term Extension Results
08/05/2025
Jolynn Tumolo
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer...
08/05/2025
Neurology

Migraine CME Series

News

An orange prescription container with generic pills spilling out in front of it
News
Antidepressant Use Not Linked to Worse Traumatic Brain Injury Outcomes
02/03/2026
Brionna Mendoza
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study...
02/03/2026
Psych Congress Network
a mother and daughter sit at a table
News
Fremanezumab Reduces Migraine Days in Pediatric Episodic Migraine
01/30/2026
Maria Mantas
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine. 
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine. 
In a recent randomized,...
01/30/2026
Neurology
fda building sign
News
FDA Approves Copper Histidinate Treatment for Pediatric Menkes Disease
01/19/2026
Brionna Mendoza
The US Food and Drug Administration (FDA) approved a copper histidinate (Zycubo) injection as the first treatment for Menkes disease in pediatric patients.
The US Food and Drug Administration (FDA) approved a copper histidinate (Zycubo) injection as the first treatment for Menkes disease in pediatric patients.
The US Food and Drug...
01/19/2026
Neurology
brain scans
News
Endovascular Thrombectomy Shows Durable 3-Year Benefit in Basilar Artery Occlusion
01/06/2026
Maria Mantas
Endovascular thrombectomy (EVT) provides durable functional and survival benefits for patients with acute basilar artery occlusion, according to long-term follow-up data from a randomized clinical trial. 
Endovascular thrombectomy (EVT) provides durable functional and survival benefits for patients with acute basilar artery occlusion, according to long-term follow-up data from a randomized clinical trial. 
Endovascular thrombectomy (EVT)...
01/06/2026
Neurology
A doctor prescribing medication for a pregnant woman
News
Antiseizure Medication Dose Adjustments During Pregnancy: Findings from the MONEAD Study
01/06/2026
Sarah Fleming
A new analysis from the US-based Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study, published in Neurology, examines how antiseizure medications (ASMs) were adjusted during pregnancy and early postpartum...
A new analysis from the US-based Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study, published in Neurology, examines how antiseizure medications (ASMs) were adjusted during pregnancy and early postpartum...
A new analysis from the US-based...
01/06/2026
Neurology
A doctor fills out a form while meeting with a patient
News
AAN Issues Evidence-Based Guideline for Management of Functional Seizures
12/18/2025
Sarah Fleming
A new clinical practice guideline from the American Academy of Neurology (AAN), published in Neurology, provides comprehensive recommendations for diagnosing and managing functional seizures.
A new clinical practice guideline from the American Academy of Neurology (AAN), published in Neurology, provides comprehensive recommendations for diagnosing and managing functional seizures.
A new clinical practice...
12/18/2025
Neurology
A doctor reviews test results with an older female patient
News
Late-Window IV Thrombolysis Before Transfer May Improve Stroke Outcomes
12/17/2025
Sarah Fleming
A multicenter study suggests that extended-window IV thrombolysis before thrombectomy transfer may enhance outcomes and recanalization in AIS-LVO without increasing hemorrhagic risk.
A multicenter study suggests that extended-window IV thrombolysis before thrombectomy transfer may enhance outcomes and recanalization in AIS-LVO without increasing hemorrhagic risk.
A multicenter study suggests...
12/17/2025
Neurology
News
Fine Particulate Air Pollution Linked to Greater Alzheimer Neuropathology, Study Finds
12/16/2025
Grace Taylor, MS, MA
Research published in JAMA Neurology links higher exposure to fine particulate air pollution (PM2.5) with more severe Alzheimer-related brain changes and faster cognitive decline in older adults.
Research published in JAMA Neurology links higher exposure to fine particulate air pollution (PM2.5) with more severe Alzheimer-related brain changes and faster cognitive decline in older adults.
Research published in JAMA...
12/16/2025
Annals of Long-Term Care
a man lies in bed sleeping while wearing a CPAP machine
News
Untreated Sleep Apnea Nearly Doubles Parkinson Disease Risk
12/09/2025
Brionna Mendoza
Obstructive sleep apnea (OSA) appears to nearly double the risk for later development of Parkinson disease (PD), but early continuous positive airway pressure (CPAP) treatment may attenuate that risk by 30%.
Obstructive sleep apnea (OSA) appears to nearly double the risk for later development of Parkinson disease (PD), but early continuous positive airway pressure (CPAP) treatment may attenuate that risk by 30%.
Obstructive sleep apnea (OSA)...
12/09/2025
Neurology
Two doctors review research data on a computer in a lab
News
Deramiocel Meets Key Endpoints in Phase 3 HOPE-3 Duchenne Trial
12/05/2025
Brionna Mendoza
Deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), met its primary and secondary endpoints in the phase 3 HOPE-3 trial, according to Capricor Therapeutics.
Deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), met its primary and secondary endpoints in the phase 3 HOPE-3 trial, according to Capricor Therapeutics.
Deramiocel, an investigational...
12/05/2025
Neurology

Alzheimer's Disease CME Series

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use